Can Pfizer get Xeljanz, Xtandi pumping while it waits for pipeline help?
admin 30th April 2019 Uncategorised 0X marks the spot for Pfizer—that is, the spots where its products are struggling to live up to expectations. Analysts pointed to weaker-than-expected showings from both anti-inflammatory drug Xeljanz and cancer-fighter Xtandi in the first quarter.
More: Can Pfizer get Xeljanz, Xtandi pumping while it waits for pipeline help?
Source: fierce
